Advertisement

Chronic Pain in End-Stage Renal Disease

  • Sara N. Davison
    Correspondence
    Address correspondence to Sara N. Davison, MD, MHSc (bioethics), FRCP(C), Division of Nephrology and Immunology, University of Alberta, Edmonton, Alberta, Canada
    Affiliations
    Division of Nephrology and Immunology, University of Alberta, Edmonton, Alberta, Canada
    Search for articles by this author
      A growing body of literature has shown that chronic pain is common for patients with end-stage renal disease (ESRD), is typically moderate or severe, and impacts virtually every aspect of health-related quality of life. Unfortunately, there is a lack of clinical and research focus in this area in nephrology, and pain in ESRD is undertreated. This article will review the epidemiology of chronic pain in ESRD, discuss basic principles of pain assessment and management, and highlight some of the challenges in pain management in ESRD with the hope of guiding health professionals in the effective management of pain in patients with ESRD.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Merskey H.
        • Bogduk N.
        Classification of Chronic Pain.
        in: International Association for the Study of Pain Press, Seattle, WA1994: 210
        • Davison S.N.
        Pain in hemodialysis patients.
        Am J Kidney Dis. 2003; 42: 1239-1247
        • Fainsinger R.
        • Davison S.N.
        • Brenneis C.
        A supportive care model for dialysis patients.
        Palliat Med. 2003; 17: 81-82
        • Fortina F.
        • Agllata S.
        • Ragazzoni E.
        • et al.
        Chronic pain during dialysis.
        Minerva Urol Nefrol. 1999; 51: 85-87
        • Cohen L.M.
        • Germain M.
        • Poppel D.M.
        • et al.
        Dialysis discontinuation and withdrawal of dialysis.
        Am J Kidney Dis. 2000; 36: 140-144
        • Sanders S.H.
        Chronic pain.
        Ann Behav Med. 1985; 7: 3-5
        • Von Korff M.
        • Dworkin S.F.
        • Le Resche L.
        • et al.
        An epidemiologic comparison of pain complaints.
        Pain. 1988; 32: 173-183
        • Kimmel P.L.
        • Emont S.L.
        • Newmann J.M.
        • et al.
        ESRD patient quality of life.
        Am J Kidney Dis. 2003; 42: 713-721
        • Davison S.N.
        The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients.
        J Pain Sympt Manage. 2005 (in press)
        • Saunders C.
        The Management of Terminal Illness.
        Edward Arnold, London1967
        • Joishy S.K.
        Palliative Medicine Secrets.
        Hanley & Belfus Inc, Philadelphia, PA1999 (, pp 1–231)
        • Bailie G.R.
        • Mason N.A.
        • Bragg-Gresham J.L.
        • et al.
        Analgesic prescription patterns among hemodialysis patients in the DOPPS.
        Kidney Int. 2004; 65: 2419-2425
        • McQuay H.
        • Moore A.
        An Evidence Based Resource for Pain Relief.
        Oxford University Press, Oxford1988
        • Zech D.F.J.
        • Ground S.
        • Lynch J.
        • et al.
        Validation for World Health Organization Guidelines for cancer pain relief.
        Pain. 1995; 63: 65-76
        • Cleeland C.
        • Gonin R.
        • Hatfield A.K.
        • et al.
        Pain and its treatment in outpatients with metastatic cancer.
        New Eng J Med. 1994; 330: 592-596
        • Anderson K.O.
        • Mendoza T.R.
        • Valero V.
        • et al.
        Minority cancer patients and their providers.
        Cancer. 2000; 88: 1929-1938
        • Chauvin M.
        • Sandouk P.
        • Scherrmann J.M.
        • et al.
        Morphine pharmacokinetics in renal failure.
        Anesthesiology. 1987; 66: 327-331
        • Glare P.A.
        • Walsh T.D.
        • Pippenger C.E.
        Normorphine, a neurotoxic metabolite?.
        Lancet. 1990; 335: 725-726
        • Hagen N.A.
        • Foley K.M.
        • Cerbone D.J.
        • et al.
        Chronic nausea and morphine-6-glucuronide.
        J Pain Symptom Manage. 1991; 6: 125-128
        • Pasternak G.W.
        • Bodnar R.J.
        • Clark J.A.
        Morphine-6-glucuronide, a potent Mu agonist.
        Life Sci. 1987; 41: 2845-2849
        • Sear J.W.
        • Hand C.W.
        • Moore R.A.
        • et al.
        Studies on morphine disposition.
        Br J Anaesth. 1989; 62: 28-32
        • Hanna M.H.
        • D’Costa F.
        • Peat S.J.
        • et al.
        Morphine-6-glucuronide disposition in renal impairment.
        Br J Anaesth. 1993; 70: 511-514
        • Bruera E.
        • Sloan P.
        • Mount B.
        • Canadian Palliative Care Clinical Trials Group
        A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain.
        J Clin Oncol. 1996; 14: 1713-1717
        • Dunbar P.J.
        • Chapman C.R.
        • Buckley F.P.
        • et al.
        Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA.
        Pain. 1996; 68: 265-270
        • Valner J.J.
        • Steward J.T.
        • Kotzan J.A.
        • et al.
        Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects.
        J Clin Pharmacol. 1981; 21: 152-156
        • Quigley C.
        Hydromorphone for acute and chronic pain.
        Cochrane Database Syst Rev CD003447. 2002
        • Sarhill N.
        • Walsh D.
        • Nelson K.A.
        Hydromorphone.
        Supportive Care in Cancer. 2001; 9: 84-96
        • Babul N.
        • Darke A.C.
        • Hage N.
        Hydromorphone metabolite accumulation in renal failure.
        J Pain Symptom Manage. 1995; 10: 184-186
        • Hagen N.
        • Swanson R.
        Multifocal myoclonus and seizures in extremely high dose opioid administration.
        Proceedings of the American Academy of Neurology. 1993
        • Fainsinger R.
        • Schoeller T.
        • Boiskin M.
        • et al.
        Palliative care round.
        J Palliat Care. 1993; 9: 53-55
        • Lee M.A.
        • Leng M.E.
        • Tiernan E.J.
        Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine.
        Palliat Med. 2001; 15: 26-34
        • Hardman J.G.
        • Goodman Gilman A.
        • Limbird L.E.
        Goodman & Gilman’s The Pharmacological Basis of Therapeutics (ed 9) (CD ROM version).
        McGraw Hill, Health Professionals Division, New York, NY1996
        • Davies A.M.
        • Inturrisi J.
        d-methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia.
        J Pharmacol Exp Ther. 1999; 289: 1048-1053
        • Hewitt D.J.
        The use of NMDA-receptor antagonists in the treatment of chronic pain.
        Clin J Pain. 2000; 16: S73-S79
        • Bruera E.
        • Neumann C.M.
        Role of methadone in the management of pain in cancer patients.
        Oncology. 1999; 13: 1275-1288
        • Gourlay G.K.
        • Cherry D.A.
        • Cousins M.J.
        A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer pain.
        Pain. 1986; 25: 297-312
        • Morrison J.D.
        • Loan W.B.
        • Dundee J.W.
        Controlled comparison of the efficacy of fourteen preparations in the relief of post-operative pain.
        Br Med J. 1971; 2: 287-290
        • Dole V.P.
        • Kreek M.J.
        Methadone plasma level.
        Proc Natl Acad Sci U S A. 1973; 70: 10-15
        • Pohland A.
        • Boaz H.E.
        • Sullivan H.R.
        Synthesis and identification of metabolites resulting from the biotransformation of d,1-methadone in man and in the rat.
        J Med Chem. 1971; 14: 194-197
        • Furlan V.
        • Hafi A.
        • Dessalles M.C.
        • et al.
        Methadone is poorly removed by hemodialysis.
        Nephrol Dial Transplant. 1999; 14: 254-255
        • Kreek M.J.
        • Schecter A.J.
        • Gutjahr C.L.
        • et al.
        Methadone use in patients with chronic renal disease.
        Drug Alcohol Dependencies. 1980; 5: 197-205
        • Mather L.E.
        Clinical pharmacokinetics of fentanyl and its newer derivatives.
        Clin Pharmakinet. 1983; 8: 422-446
        • Paix A.
        • Coleman A.
        • Lees J.
        • et al.
        Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer management.
        Pain. 1995; 63: 263-269
        • Zech D.F.J.
        • Grond S.U.A.
        • Lynch J.
        • et al.
        Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain.
        Pain. 1992; 50: 293-301
        • McClain D.A.
        • Hug Jr, C.C.
        Intravenous fentanyl kinetics.
        Clin Pharmacol Ther. 1980; 28: 106-114
        • Bower S.
        Plasma protein binding of fentanyl.
        J Pharm Pharmacol. 1982; 34: 102-106
        • Koehntop D.E.
        • Rodman J.H.
        Fentanyl pharmacokinetics in patients undergoing renal transplantation.
        Pharmacotherapy. 1997; 17: 745-752
        • Corall I.M.
        • Moore A.R.
        • Strunin L.
        Plasma concentrations of fentanyl in normal surgical patients and those with severe renal and hepatic disease.
        Br J Anaesth. 1980; 52: 101
        • Koren G.
        • Crean P.G.G.V.
        • Klein J.
        • et al.
        Pharmacokinetics of fentanyl in children with renal disease.
        Res Commun Chem Pathol Pharmacol. 1984; 46: 371-379
        • Mercandante S.
        • Caligara M.
        • Sapio M.
        • et al.
        Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure.
        J Pain Symptom Manage. 1997; 13: 241-244
        • Serlin R.C.
        • Mendoza T.R.
        • Nakamura Y.
        • et al.
        When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.
        Pain. 1995; 61: 277-284
        • Kurella M.
        • Bennett W.M.
        • Chertow G.M.
        Analgesia in patients with ESRD.
        Am J Kidney Dis. 2003; 42: 217-228
        • Ferro C.J.
        • Davison S.N.
        • Chambers E.J.
        Management of pain in renal failure.
        in: Chambers E.J. Germain M. Brown E. Supportive Care for the Renal Patient. Oxford University Press, Oxford, UK2004: 105-142
        • Henrich W.L.
        • Agodoa L.E.
        • Barrett B.
        • et al.
        Analgesics and the kidney.
        Am J Kidney Dis. 1996; 27: 162-165
        • Cohen L.M.
        • Reiter G.S.
        • Poppel D.M.
        • et al.
        Palliative Care for Non-Cancer Patients.
        in: Oxford University Press, New York, NY2001: 103-113